Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pyruvate kinase isoform M2 (PKM2) is a key glycolytic enzyme that catalyzes the final step of glycolysis, converting phosphoenolpyruvate to pyruvate and ATP. It is highly expressed in tumor cells and plays a central role in metabolic reprogramming (Warburg effect), promoting aerobic glycolysis to support rapid cell proliferation. PKM2 also has non-metabolic roles, including protein kinase activity and regulation of gene expression. It is considered a promising target for anti-cancer therapies, with strategies focusing on modulating its oligomerization state or inhibiting its kinase activity.
Modulation of PKM2 oligomerization; Inhibition of PKM2 kinase activity; Targeting PKM2 nuclear function
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pyruvate Kinase Isoform M2 (PKM2).